This study is looking at a new treatment called RP2, which is a modified virus designed to fight cancer and boost your immune system. It's being tested alone or with other approved cancer drugs like atezolizumab, bevacizumab, and durvalumab. This study is for people with advanced liver cancer (hepatocellular carcinoma or HCC) or biliary tract cancer that cannot be removed by surgery or has spread. Researchers want to see how well these treatments shrink tumors (Overall Response Rate) and if they are safe. The study aims to enroll 60 participants aged 18 and older.

Study design

This is a Phase 2, open-label study, meaning both you and your doctors will know which treatment you are receiving. It plans to include 60 participants.

What's involved

You would have a screening period of 28 days, followed by a treatment period with regular tumor assessments. These assessments happen every 8 or 9 weeks, depending on your cancer type.

Compensation

Not stated in the trial record.

Follow-up

After treatment, your safety will be monitored for 30 to 135 days, and tumor assessments will continue every 12 weeks. Survival information will be collected for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.